Drugs / SAR444336
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05876767 | Oct 2021 → Dec 2023 | — | Sanofi | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07156175 | Oct 2025 → Apr 2027 expected | microscopic colitis | Sanofi | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR444336 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05876767 ↗ |
| Route | Subcutaneous | “Single or repeated dose subcutaneous injection” NCT05876767 ↗ |